@article{7d4c420c204641a59ca9be0dbf9e0575,
title = "Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults",
abstract = "Background: Exposure to surgery with general anaesthesia (surgery/GA) is associated with cortical atrophy, but the aetiology remains unknown. Amyloid-β (Aβ) deposition is one of the hallmark pathological characteristics of Alzheimer's disease (AD). We examined brain Aβ burden in study participants exposed to surgery/GA. Methods: We performed a cross-sectional analysis of residents of Olmsted County, MN, USA, in the Mayo Clinic Study of Aging who were aged 70–97 yr and underwent measurement of (i) brain Aβ with Pittsburgh compound B positron emission tomography (PiB PET), (ii) brain glucose metabolism with 18-fluorodeoxyglucose (FDG) PET, and (iii) temporal cortical thickness with MRI. Separate analyses were performed with exposure to surgery/GA, defined as occurring after age 40 yr, and with exposure to surgery/GA, defined as occurring within 20 yr before neuroimaging. Imaging measurements were compared between participants who were exposed to surgery/GA vs not exposed. Results: Of the 2563 participants, 585 had PET scans. Regardless of the definition used to quantify exposure, no significant associations were detected between exposure and either global PiB PET or FDG PET. In contrast, exposure to surgery/GA was associated with an increased likelihood of abnormal cortical thinning: odds ratio (OR)=1.98 (95% confidence interval [CI]: 1.19–3.31); P=0.010 in those exposed after age 40 yr, and OR=1.64 (95% CI: 1.05–2.55); P=0.029 in those exposed in the prior 20 yr. Conclusions: Exposure to surgery/GA is not associated with increases in cortical amyloid deposition. This finding suggests that the modest cortical thinning associated with surgery/GA is not related to AD pathology, but rather is caused by other processes.",
keywords = "Alzheimer's disease, MRI, Mayo Clinic Study of Aging, brain amyloid, general anaesthesia, neurodegeneration, positron emission tomography, surgery",
author = "Juraj Sprung and Warner, {David O.} and Knopman, {David S.} and Petersen, {Ronald C.} and Mielke, {Michelle M.} and Jack, {Clifford R.} and Lowe, {Val J.} and Martin, {David P.} and Hanson, {Andrew C.} and Schroeder, {Darrell R.} and Przybelski, {Scott A.} and Schulte, {Phillip J.} and Weingarten, {Toby N.} and Prashanthi Vemuri",
note = "Funding Information: National Institutes of Health ( U01 AG006786 ) to RCP; ( P50 AG016574 ) to RCP; ( RF1 AG055151 ) to MMM; ( R01 AG041851 ) to CRJ and DSK; ( R37 AG011378 ) to CRJ; ( R01 NS097495 ) to PV; ( R01 AG056366 ) to PV; Robert H. and Clarice Smith and Abigail van Buren Alzheimer's Disease Research Program; Elsie & Marvin Dekelboum Family Foundation ; Liston Family Foundation; Rochester Epidemiology Project ( R01 AG034676 ); Mayo Clinic Center for Translational Sciences Activities ; National Center for Advancing Translational Sciences ( UL1 TR000135 ). Funding Information: DSK previously served as deputy editor for the journal Neurology, and serves on a Data Safety Monitoring Board for Lundbeck and for the Dominantly Inherited Alzheimer Network Trials Unit. He is an investigator in clinical trials sponsored by Biogen , Eli Lilly and Company , University of Southern California , and TauRx Therapeutics Limited , and receives research support from the National Institutes of Health . RCP is chair of the Data Monitoring Committees for Pfizer, GE Healthcare, and Janssen Alzheimer Immunotherapy, and has served as a consultant for F. Hoffmann-La Roche, Biogen, Eisai, Merck and Co., and Genentech. He receives royalties from the sales of the book Mild Cognitive Impairment (Oxford University Press). The other authors declare that they have no conflicts of interest. Funding Information: DSK previously served as deputy editor for the journal Neurology, and serves on a Data Safety Monitoring Board for Lundbeck and for the Dominantly Inherited Alzheimer Network Trials Unit. He is an investigator in clinical trials sponsored by Biogen, Eli Lilly and Company, University of Southern California, and TauRx Therapeutics Limited, and receives research support from the National Institutes of Health. RCP is chair of the Data Monitoring Committees for Pfizer, GE Healthcare, and Janssen Alzheimer Immunotherapy, and has served as a consultant for F. Hoffmann-La Roche, Biogen, Eisai, Merck and Co., and Genentech. He receives royalties from the sales of the book Mild Cognitive Impairment (Oxford University Press). The other authors declare that they have no conflicts of interest.National Institutes of Health (U01 AG006786) to RCP; (P50 AG016574) to RCP; (RF1 AG055151) to MMM; (R01 AG041851) to CRJ and DSK; (R37 AG011378) to CRJ; (R01 NS097495) to PV; (R01 AG056366) to PV; Robert H. and Clarice Smith and Abigail van Buren Alzheimer's Disease Research Program; Elsie & Marvin Dekelboum Family Foundation; Liston Family Foundation; Rochester Epidemiology Project (R01 AG034676); Mayo Clinic Center for Translational Sciences Activities; National Center for Advancing Translational Sciences (UL1 TR000135). Publisher Copyright: {\textcopyright} 2020 British Journal of Anaesthesia",
year = "2020",
month = may,
doi = "10.1016/j.bja.2020.01.015",
language = "English (US)",
volume = "124",
pages = "594--602",
journal = "British Journal of Anaesthesia",
issn = "0007-0912",
publisher = "Oxford University Press",
number = "5",
}